Nicotine Testing: The Ethics of Screening for Tobacco Use in Healthcare and Employment

In 2022, a major U.S. healthcare system announced that it would no longer hire anyone who tested positive for nicotine—not just smokers, but users of any nicotine product, including patches, gum, and e-cigarettes. The policy, justified as promoting a 'culture of wellness,' meant that a nurse who used nicotine gum to manage stress during grueling shifts was ineligible for employment at the very institution that prescribed the gum. The policy was legal in most U.S. states, where nicotine users are not a protected class and employers have near-total discretion over hiring criteria. It was also, a growing number of ethicists and public health experts argue, profoundly misguided—a confusion of health promotion with moral judgment that punishes the most stigmatized health behavior while doing nothing to address the addiction that drives it.

Nicotine testing in healthcare and employment has expanded dramatically in the 21st century, driven by several converging forces. Healthcare systems, self-insured for employee health costs, have a direct financial incentive to exclude nicotine users—smokers cost employers an estimated $6,000 more per year in healthcare expenditures and lost productivity. The Affordable Care Act in the U.S. allows insurers to charge tobacco users up to 50% more for health insurance premiums, creating a further financial incentive for both individuals and employers to screen and penalize. And the cultural shift toward 'wellness' as a corporate value has provided ideological cover for policies that would have been seen as intrusively paternalistic a generation ago. The result is a landscape where nicotine use, uniquely among legal health behaviors, is treated as a disqualifying moral condition.

The disparate impact of nicotine testing falls heavily along lines of class, race, and mental health status. Smoking is increasingly concentrated in low-income populations, people with mental illness (who smoke at rates two to three times the general population), and certain racial and ethnic minority groups. A hiring policy that excludes nicotine users is, in effect, a policy that disproportionately excludes poor people, people with mental health conditions, and people of color—even if the policy is facially neutral. This is not a hypothetical concern. The American Civil Liberties Union and several public health law scholars have argued that nicotine-free hiring policies may violate employment discrimination laws under a disparate-impact theory, though the legal question remains unsettled. What's clear is that nicotine testing functions as a socioeconomic screen, and that its proponents rarely acknowledge—or perhaps even recognize—this dimension.

The distinction between smoking and nicotine use is almost universally erased in nicotine testing policies, with perverse consequences. A hospital that refuses to hire someone who uses nicotine gum or an e-cigarette to stay off cigarettes is penalizing the very behavior—successful smoking cessation—that the policy ostensibly promotes. A 2024 survey found that 12% of vapers reported avoiding switching from smoking to vaping specifically because they feared losing their jobs or facing higher insurance premiums under nicotine-free workplace policies. The policies that are supposed to improve health are, for some smokers, a barrier to harm reduction. This is not a wrinkle that can be ironed out with better policy design. It's a fundamental contradiction between the logic of abstinence-only nicotine policies and the reality of nicotine addiction as a chronic, relapsing condition that many people manage rather than 'cure.'

The ethical framework for nicotine testing rests on contested assumptions about personal responsibility and health. Proponents argue that smoking is a behavior, not an immutable characteristic, and that employers and insurers have a legitimate interest in distinguishing between health conditions that individuals didn't choose (genetic predispositions, congenital conditions) and those they did (smoking, diet, exercise). The Affordable Care Act's tobacco surcharge framework explicitly adopts this logic. Opponents argue that addiction undermines the voluntariness of smoking—that nicotine dependence is, by definition, a condition in which the capacity for free choice is compromised. The neurobiology supports both positions: nicotine addiction is not a simple failure of willpower, but neither is it a condition that removes all agency. People with addiction make choices, including the choice to seek treatment. But those choices are constrained by neural circuits that have been altered by the very substance the choice is about.

The practical alternatives to punitive nicotine testing exist and are underutilized. Several large employers, including Cleveland Clinic (which famously implemented a nicotine-free hiring policy in 2007 and then refined it over time), have shifted toward offering comprehensive cessation support—free NRT, counseling, and smoking cessation programs—as a condition of employment rather than an exclusionary criterion. The policy says: you can work here if you use nicotine, but you must enroll in our cessation program, and we'll support you in quitting. This approach acknowledges the reality of nicotine addiction while maintaining a commitment to a smoke-free workforce. It's more expensive to administer than a simple cotinine test, which is why most employers don't adopt it. The choice between testing-and-excluding and testing-and-treating is ultimately a choice about whether nicotine users are seen as moral failures to be excluded or patients to be helped.

Nicotine testing is a microcosm of a larger societal tension: the collision between the medical model of addiction (which treats it as a chronic disease requiring treatment) and the moral model (which treats it as a character flaw deserving consequences). The medical model has made enormous progress in destigmatizing other substance use disorders. Increasingly, opioid use disorder is understood as a disease, not a moral failing, and medication-assisted treatment is standard of care. Nicotine addiction, despite affecting far more people, remains stubbornly moralized—seen as a 'bad habit' rather than a chronic brain disease, its victims blamed for their condition in ways that would be considered cruel if applied to alcohol or opioid dependence. The nicotine test is the physical manifestation of this double standard: a technology that purports to measure a health behavior but actually measures social worth, sorting the deserving from the undeserving with the precision of a laboratory assay.